Orientbio KRX:002630KOSPI
오리엔트바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked10since Sep 11
In Q2 2026, Orientbio reported revenue of ₩6.6bn, down 14.2% year on year, and operating profit of ₩50m. Orientbio (오리엔트바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Turnaround Screener
Orientbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.6bn | -14.2% | ₩50m margin 0.8% | ₩4.8bn |
| Q4 2025 | ₩8.6bn | -4.0% | −₩1.6bn margin −18.2% | −₩1.9bn |
| Q3 2025 | ₩6.9bn | +3.0% | −₩680m margin −9.8% | −₩151m |
| Q2 2025 | ₩7.7bn | +4.0% | −₩1.6bn margin −21.1% | −₩2.0bn |
| Q1 2025 derived | ₩6.3bn | -1.0% | −₩583m margin −9.2% | −₩4.1bn |
| Q4 2024 | ₩9.0bn | +9.4% | −₩1.7bn margin −19.3% | −₩1.3bn |
| Q3 2024 | ₩6.7bn | – | −₩691m margin −10.3% | −₩1.1bn |
| Q2 2024 | ₩7.4bn | – | −₩67m margin −0.9% | −₩6.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Orientbio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Orientbio news Korean headlines
-
오리엔트바이오 "고품질 SPF 연구용 토끼 공급 확대"
2 more on this story · 2 outlets
- 오리엔트바이오, 고품질 SPF 연구용 토끼 공급 확대아시아경제 · Oct 12 08:26
- 오리엔트바이오, 고품질 SPF 연구용 토끼 공급 확대뉴스핌 · Oct 12 13:37
-
오리엔트바이오, 무상감자 완료…거래 재개
4 more on this story · 4 outlets
- 오리엔트바이오, 무상감자 절차 완료…거래 재개뉴시스경제 · Sep 22 08:17
- 오리엔트바이오 "무상감자 절차 완료 ... 오늘부터 거래 재개"한국경제 · Sep 22 08:21
- 오리엔트바이오, 2대1 무상감자 완료…거래 재개뉴스핌 · Sep 22 08:59
- 오리엔트바이오, 무상감자 절차 종료...주식 거래 재개파이낸셜뉴스 · Sep 22 10:25